Developer of inhaled insulin products to intended to replace of diabetes injections and pills. The company develops and produces a pocket-sized inhaler device and insulin container for the treatment of type 1 and 2 diabetes which includes preservative free formulation of inhaled recombinant human insulin delivered via a proprietary, smart, handheld soft mist device, enabling convenient and confident delivery of insulin into a patient's lungs in just a few breaths yielding high lung deposition and distribution.
Generating Revenue
Privately Held (backing)
Private Equity-Backed
The company received $24.5 million of development capital from Molex Ventures and other undisclosed investors on September 19, 2018. The funding enables the company to support human clinical studies and manufacture drug and devices for clinical studies.
Add a review